SEC Form 10-Q filed by 60 Degrees Pharmaceuticals Inc.
$SXTP
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)
8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)
8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)
424B5 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)
Breakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA)Results obtained using highest sensitivity test available; licensed by FDA for blood donation screeningRemaining enrolled patients will complete the study between January and October 2026Study intended to confirm the high cure rate for tafenoquine in immunosuppressed patients with relapsing babesiosis, as reported by Yale in a 2024 publication WASHINGTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical com
Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competitionA $5K donation from the Company was split between ILADEF and GLA to recognize the winning nameB-FREE, a Phase 2 trial, will commence in early November and run for approximately 12 months WASHINGTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today the name of its chronic babesiosis trial is the B-FREE Chronic Babesiosis Study. The B-FREE study (NCT06656351), the first in the world to evaluate a pote
WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today the webcast link and change of date for management's live presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, to Tuesday, September 9, 3:30 PM Eastern Time. Dr. Geoff Dow, 60 Degrees Pharma CEO, will present live and management will conduct one-on-one meetings during the conference. Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 9, 2025Time: 3:30 PM ETLocation: Lotte N
ORLANDO, FL / ACCESSWIRE / December 2, 2024 / RedChip Companies aired interviews with VSee Health, Inc. (NASDAQ:VSEE) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV on November 30. Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:VSEE: https://www.redchip.com/assets/access/vsee_accessSXTP: https://www.redchip.com/assets/access/sxtp_accessIn an exclusive interview, Imo Aisiku, M.D., co-CEO and Chairman of VSee Health, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share insight into how VSee Health's differentiated so
ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Can-Fite BioPharma Ltd. (NYSE:CANF)(TASE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:SXTP: https://www.redchip.com/assets/access/sxtp_accessCANF: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on
MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to advise that RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and 60 Degrees Pharmaceuticals (60P) (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: • Genetic Technologies (NASDAQ:GENE): https://www.redchip.com/
SC 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)
SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)
SC 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)